Results 51 to 60 of about 633,971 (314)

The interactions of SARS-CoV-2 with co-circulating pathogens: Epidemiological implications and current knowledge gaps [PDF]

open access: yesarXiv, 2022
Despite the availability of effective vaccines, the persistence of SARS-CoV-2 suggests that co-circulation with other pathogens and resulting multi-epidemics may become increasingly frequent. To better forecast and control the risk of such multi-epidemics, it is essential to elucidate the potential interactions of SARS-CoV-2 with other pathogens; these
arxiv  

Challenges to estimating vaccine impact using hospitalization data. [PDF]

open access: yes, 2017
Because the real-world impact of new vaccines cannot be known before they are implemented in national programs, post-implementation studies at the population level are critical.
Bruhn, Christian AW   +6 more
core   +3 more sources

Pneumococcal Vaccines

open access: yesIndian Journal of Medical Microbiology, 2018
Streptococcus pneumoniae continues to take a heavy toll on childhood mortality and morbidity across the developing world. An estimated 10.6 million invasive pneumococcal diseases (IPDs) occur every year, with nearly 1 million deaths in children under 5 years of age. Introduction of vaccines in the childhood immunisation programme in developed world has
Anand, Manoharan, Ranjith, Jayaraman
openaire   +2 more sources

Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis.

open access: yesRheumatology, 2016
OBJECTIVES The aim was to assess the immunogenicity and the impact on disease activity of pneumococcal and influenza vaccines in SLE patients. METHODS We conducted a systematic literature review and meta-analysis of studies comparing the humoral ...
M. Puges   +8 more
semanticscholar   +1 more source

Seasonality and outbreak of a predominant Streptococcus pneumoniae serotype 1 clone from The Gambia: expansion of ST217 hypervirulent clonal complex in West Africa. [PDF]

open access: yes, 2008
BACKGROUND: Streptococcus pneumoniae serotype 1 causes > 20% of invasive disease, among all age groups combined, in The Gambia. In contrast, it is rarely detected in carriage studies. This study compares the molecular epidemiology of S.
Adegbola, Richard A   +15 more
core   +2 more sources

Molecular surveillance of nasopharyngeal carriage of Streptococcus pneumoniae in children vaccinated with conjugated polysaccharide pneumococcal vaccines

open access: yesScientific Reports, 2016
Following the introduction of pneumococcal conjugate vaccines (PCVs) for infants, surveillance studies on Streptococcus pneumoniae carriage have proven valuable for monitoring vaccine effects.
A. Wyllie   +10 more
semanticscholar   +1 more source

CLINICAL AND IMMUNOLOGICAL EFFECT OF PNEUMOCOCCAL CONJUGATED VACCINES IN IMMUNOCOMPROMISED PATIENTS

open access: yesПедиатрическая фармакология, 2010
Invasive pneumococcal infection is the most frequent cause of death in patients with immunodeficiences. The antibiotics used previously for prevention purposes are not efficient enough due to the developing antibiotic resistance.
A.A. Tarasova, M.P. Kostinov
doaj   +2 more sources

VaccineLies: A Natural Language Resource for Learning to Recognize Misinformation about the COVID-19 and HPV Vaccines [PDF]

open access: yesarXiv, 2022
Billions of COVID-19 vaccines have been administered, but many remain hesitant. Misinformation about the COVID-19 vaccines and other vaccines, propagating on social media, is believed to drive hesitancy towards vaccination. The ability to automatically recognize misinformation targeting vaccines on Twitter depends on the availability of data resources.
arxiv  

Rationale and prospects for novel pneumococcal vaccines

open access: yesHuman Vaccines & Immunotherapeutics, 2016
Streptococcus pneumoniae remains one of the most frequent bacterial causes of morbidity and mortality worldwide. National immunization programs implementing pneumococcal polysaccharide conjugate vaccines (PCVs) have successfully reduced rates of vaccine ...
K. Moffitt, R. Malley
semanticscholar   +1 more source

Adult indication 13-valent pneumococcal conjugate vaccine clinical development overview: formulation, safety, immunogenicity (dosing and sequence), coadministration, and efficacy

open access: yesExpert Review of Vaccines
Introduction There was no 13-valent pneumococcal conjugate vaccine (PCV13) adult antibody concentration threshold regulatory criterion for licensure – unlike the pediatric indication; consequently, for the adult indication, PCV13 serotype-specific ...
Mark A. Fletcher   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy